# MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation

> **NCT00256776** · PHASE3 · TERMINATED · sponsor: **European Society for Blood and Marrow Transplantation** · enrollment: 269 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Velcade (Bortezomib)
- **DRUG:** Thalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT00256776
- **Lead sponsor:** European Society for Blood and Marrow Transplantation
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-07
- **Primary completion:** 2013-12
- **Final completion:** 2015-12
- **Target enrollment:** 269 (ACTUAL)
- **Last updated:** 2021-10-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00256776

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00256776, "MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00256776. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*